MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
22.72
+1.74
+8.29%
Pre Market: 22.71 -0.01 -0.04% 05:12 01/08 EST
OPEN
21.62
PREV CLOSE
20.98
HIGH
22.74
LOW
21.56
VOLUME
178
TURNOVER
0
52 WEEK HIGH
45.30
52 WEEK LOW
20.21
MARKET CAP
4.20B
P/E (TTM)
-17.4514
1D
5D
1M
3M
1Y
5Y
1D
LEGEND BIOTECH CORP <LEGN.O>: RBC CUTS TARGET PRICE TO $66 FROM $74
Reuters · 18m ago
Is Legend Biotech (LEGN) Pricing Reflect Recent 37.5% Share Price Slide And DCF Upside Potential
Simply Wall St · 19h ago
Legend Biotech Price Target Announced at $75.00/Share by Oppenheimer
Dow Jones · 20h ago
Oppenheimer Initiates Coverage On Legend Biotech with Outperform Rating, Announces Price Target of $75
Benzinga · 20h ago
Legend Biotech initiated with an Outperform at Oppenheimer
TipRanks · 22h ago
Weekly Report: what happened at LEGN last week (1229-0102)?
Weekly Report · 3d ago
Weekly Report: what happened at LEGN last week (1222-1226)?
Weekly Report · 12/29/2025 10:34
Can Amgen Sustain Its Rally In 2026
Seeking Alpha · 12/26/2025 18:03
More
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.